pyruvic acid has been researched along with Muscle Weakness in 2 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
Muscle Weakness: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The long-term effects of the sodium salt of dichloroacetic acid (DCA) were evaluated in four patients with mitochondrial encephalomyelopathy with lactic acidosis and stroke-like episodes (MELAS) carrying A3243G mutation." | 5.11 | Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. ( Goto, T; Momoi, MY; Mori, M; Saito, S; Yamagata, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hiraki, N | 1 |
| Tanaka, TD | 1 |
| Yoshimura, M | 1 |
| Mori, M | 1 |
| Yamagata, T | 1 |
| Goto, T | 1 |
| Saito, S | 1 |
| Momoi, MY | 1 |
1 trial available for pyruvic acid and Muscle Weakness
| Article | Year |
|---|---|
Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Chemical and Drug Induced Liver Injury; Child; Dic | 2004 |
1 other study available for pyruvic acid and Muscle Weakness
| Article | Year |
|---|---|
A Man With Left Ventricular Hypertrophy.
Topics: Adult; Atrophy; Cardiomyopathies; Cerebellar Diseases; Cognitive Dysfunction; Echocardiography; Gluc | 2022 |